This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Moskovits, N. Articles by Oren, M. Search for Related Content PubMed PubMed Citation Articles by Moskovits, N. Articles by Oren, M.

p53 Attenuates Cancer Cell Migration and Invasion through Repression of SDF-1/CXCL12 Expression in Stromal Fibroblasts

Departments of ¹ Molecular Cell Biology and ² Immunology, The Weizmann Institute of Science, Rehovot, Israel and ³ Department of Oncology, Sheba Medical Center, Tel Hashomer, Israel

Requests for reprints: Moshe Oren, Department of Molecular Cell Biology, The Weizmann Institute, P.O. Box 26, Rehovot 76100, Israel. Phone: 972-8-934-2358; Fax: 972-8-934-6004; E-mail: moshe.oren{at}weizmann.ac.il.

The p53 tumor suppressor acts as a major barrier against cancer. To a large extent, this is due to its ability to maintain genome stability and to eliminate cancer cells from the replicative pool through cell-autonomous mechanisms. However, in addition to its well-documented functions within the malignant cancer cell, p53 can also exert non-cell-autonomous effects that contribute to tumor suppression. We now report that p53 can suppress the production of the chemokine SDF-1 in cultured fibroblasts of both human and mouse origin. This is due to a p53-mediated down-regulation of SDF-1 mRNA, which can be exacerbated on activation of p53 by the drug Nutlin-3. SDF-1 promotes the migration and invasiveness of cells that express its cognate receptor CXCR4. Indeed, medium conditioned by p53-deficient fibroblasts induces cancer cells towards increased directional migration and invasiveness, which are largely reversed by CXCR4 antagonist peptides. Because SDF-1 produced by stromal fibroblasts plays an important role in cancer progression and metastasis, our findings suggest that the ability of p53 to suppress stromal SDF-1 production may be an important mechanism whereby it does its non-cell-autonomous tumor suppressor function. (Cancer Res 2006; 66(22): 10671-6)

This article has been cited by other articles:

				N. M. Hawsawi, H. Ghebeh, S.-F. Hendrayani, A. Tulbah, M. Al-Eid, T. Al-Tweigeri, D. Ajarim, A. Alaiya, S. Dermime, and A. Aboussekhra Breast Carcinoma-Associated Fibroblasts and Their Counterparts Display Neoplastic-Specific Changes Cancer Res., April 15, 2008; 68(8): 2717 - 2725. [Abstract] [Full Text] [PDF]

				P. Secchiero, F. Corallini, E. Rimondi, C. Chiaruttini, M. G. di Iasio, A. Rustighi, G. Del Sal, and G. Zauli Activation of the p53 pathway down-regulates the osteoprotegerin expression and release by vascular endothelial cells Blood, February 1, 2008; 111(3): 1287 - 1294. [Abstract] [Full Text] [PDF]

				H. Hirata, Y. Hinoda, N. Kikuno, K. Kawamoto, A. V. Dahiya, Y. Suehiro, Y. Tanaka, and R. Dahiya CXCL12 G801A Polymorphism Is a Risk Factor for Sporadic Prostate Cancer Susceptibility Clin. Cancer Res., September 1, 2007; 13(17): 5056 - 5062. [Abstract] [Full Text] [PDF]